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Medical Marijuana Policy Reform Reaches 
Florida: A Scoping Review 
_______________________________________________________________________________ 
 
Khadesia Howell, MPH; Alexandria Washington, MPH; Paula M Williams, MPH; Arlesia L 
Mathis, PhD; John S Luque, PhD, MPH 
________________________________________________________________________________ 
ABSTRACT 
Background: Florida became the first state in the U.S. South to legalize the use of medical marijuana to treat a variety 
of health conditions including chronic pain, epilepsy, and spasticity symptoms from multiple sclerosis. While there are 
over 200,000 medical marijuana patients in Florida, there remain financial, psychological, and insurance coverage 
barriers which reduce access for many patients. Purpose: This scoping review, with a focus on state health policy, first 
describes some clinical studies examining the therapeutic benefits of medical marijuana. Next, there is a discussion of 
the Florida regulatory environment and major legislation. Also, the review describes how the current Florida policy 
landscape presents challenges for physicians and patients. Methods: A scoping review of the literature was conducted in 
PubMed and Google Scholar using the search terms, “medical marijuana” and “medical cannabis” to identify research 
articles, newspaper reports, and government documents. The purpose of the review was to identify research investigating 
the therapeutic efficacy of medical marijuana and state policies affecting physician practice. Results: The review 
concluded there was general scientific consensus of therapeutic benefits for patients, especially for chronic pain, from 
the use of medical marijuana. The review also identified several barriers for physicians and patients around cost, stigma, 
and lack of insurance coverage which constrains use and access. Discussion: The review discusses several directions for 
future medical marijuana policy and research with the aim to improve therapeutic benefits for Florida patients.  
 
Howell K, Washington A, Williams PM, Mathis AL, Luque JS. Medical marijuana policy reform reaches Florida: 
A scoping review. Florida Public Health Review. 2019;16:128-136. 
____________________________________________________________________________________________
BACKGROUND 
Marijuana, the dried leaves and flowers of the herbal 
plant Cannabis sativa, is the most commonly used 
illicit drug in the United States.1 Since 1970, marijuana 
has been classified as a Schedule I substance under the 
Controlled Substances Act and applied by the U.S. 
Drug Enforcement Agency (DEA). This class of 
drugs, substances, and chemicals are defined as those 
with no “currently accepted medical use and high 
potential for abuse.”2 However despite the federal ban, 
there are 33 legal medical marijuana states dating back 
to 1996, and 10 legal recreational marijuana states 
dating back to 2012.3 Florida became the first state in 
the U.S. South to allow residents to use medical 
marijuana following the passage of Ballot Amendment 
2 in 2016.4 Medical marijuana, for the purposes of this 
review, refers to botanical cannabis, rather than to any 
marijuana-derived pharmaceutical product.  
Despite the classification of marijuana as an illegal 
substance under federal law, a growing body of 
research has suggested marijuana has therapeutic 
benefits for a variety of health conditions. Clinical 
studies suggest medical marijuana may reduce 
neuropathic pain, nausea and vomiting due to 
chemotherapy, spasticity from multiple sclerosis 
(MS), intraocular pressure, and increase appetite.5,6 
Because of the Schedule 1 classification, scientific 
studies of marijuana have been extremely limited in 
the U.S., yet researchers in Canada and Europe have 
conducted clinical trials of cannabis-derived drugs 
such as Sativex®, which addresses neuropathic pain in 
MS patients.7,8 Sativex® contains a 1:1 ratio of Delta-
9-tetrahydrocannibinol (THC) to cannabidiol (CBD), 
which reduces some of the potential negative side 
effects of higher THC levels.9 To date however, the 
Food and Drug Administration (FDA) has only 
approved the use of marijuana for two rare and severe 
forms of epilepsy, which also places limits on the 
ability to cover the drug under health insurance 
plans.10 The FDA has approved one cannabis-derived 
and three cannabis-related pharmaceutical drug 
products.11 One of these products is Epidiolex® 
(derived from CBD), an oral solution for the treatment 
of seizures associated with severe forms of epilepsy. 
Another drug product is Cesamet® with the active 
ingredient nabilone, a synthetic analogue of THC, to 
treat nausea and vomiting associated with cancer 
chemotherapy. Marinol® and Syndros® are also 
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FDA-approved and contain the active ingredient 
dronabinol, another synthetic form of THC, which is 
an antiemetic used to increase appetite in patients with 
the human immunodeficiency virus and to help 
patients experiencing wasting from cancer 
chemotherapy. 
 Marijuana contains over 100 different chemicals 
which are classified as cannabinoids, chemicals which 
can be used for medicinal purposes when using the 
whole unprocessed marijuana plant or its essential 
extracts.12 The two most well-known chemicals of this 
class are THC and CBD. THC content in recreational 
marijuana in the U.S. nearly doubled between 1997 
and 2006, from 4.5% to 8.5%, which is notable 
because 1) higher THC levels are more likely to 
produce adverse psychological effects in naïve users, 
and 2) past recreational users who transition to 
medical users may be accustomed to higher THC 
levels.13 Depending on the strain, a higher percentage 
of CBD attenuates the risk of using high THC 
marijuana.14 Despite what is known about THC:CBD 
ratio combinations and their differential effects, 
medical marijuana laws do not provide guidance on 
THC levels for medical-grade marijuana.15 Figure 1 
below illustrates how a drug company or medical 
marijuana treatment center (MMTC) might explain 
how the chemicals provide therapeutic benefits to 
patients. By modifying these ratios, individualized 
treatment might be offered to patients with a variety of 
mixture types available.  
	
Figure	1.	Example	of	educational	graphic	to	explain	therapeutic	benefits	of	THC	and	CBD16	
	
	
	
	
 
Because of the trend of legalizing the use of medical 
marijuana in more than half of all states, some medical 
organizations support reclassification of marijuana at 
the federal level as a Schedule II controlled substance.7 
Furthermore, the medical marijuana treatment 
industry, pharmaceutical companies, and academia are 
invested in continuing the study of medical marijuana, 
as any other medical therapy has been studied, which 
would result in the drug being removed from the 
Schedule 1 category if the drug demonstrated 
effectiveness for certain medical conditions in 
placebo-controlled trials. However, most research has 
been limited to retrospective cohort studies, case 
studies, or observational studies creating a conundrum 
for developing an evidence base.14 Conducting more 
clinical studies would help inform physicians on 
proper dosing of cannabis-based medicines, yet the 
ability to conduct these studies is hampered by current 
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legal and policy barriers, leading to a Catch-22. More 
research is needed to measure the therapeutic benefits 
for patients how cannabinoids affect human health. 
This review begins with describing clinical studies on 
the therapeutic benefits of medical marijuana. This is 
followed by a discussion of the Florida regulatory 
environment and existing legislation which govern 
physician practice. The review also discusses barriers 
to patient access and health disparities. Marijuana, like 
any other drug therapy, involves both risks and 
benefits. There are potential harms related to chronic 
marijuana use such as the increased risk of motor 
vehicle crashes, worsening of schizophrenia or other 
related mental disorders in some individuals, and 
increased severity of respiratory symptoms, among 
other risks.17 It is with these caveats that this review 
proceeds to review the literature regarding the 
therapeutic benefits of medical marijuana and the 
current policy landscape in Florida. 
 
METHODS 
A scoping review of the literature was conducted in 
PubMed and Google Scholar using the search terms, 
“medical marijuana” and “medical cannabis” to 
identify research articles for this review.18 In addition, 
an internet search was conducted using the search 
terms, “Florida medical marijuana law” to identify 
articles in newspapers and law journals for further 
information about challenges related to the 
decriminalization of medical marijuana in the state. 
The results of the literature search were compiled into 
an Endnote database. The purpose of conducting the 
scoping review was to document recent evidence on 
the therapeutic benefits of medical marijuana and 
identify challenges for physicians and patients in the 
context of decriminalization in Florida. 
 
RESULTS 
The results from the literature search were comprised 
of primarily peer-reviewed articles (83 articles). The 
peer-reviewed articles were published between 2005 
and 2019, with the bulk of the articles published since 
2014 (74 articles). The articles primarily reported 
original research, but the literature search also 
included 14 literature review articles. Other document 
sources included government websites, Florida 
newspaper articles, Florida Bar Journal articles, 
Florida statutes, and consensus study reports (15 
documents). The Physician Certification Pattern 
Review Panel Annual Report provided detailed data 
on medical marijuana recommendation patterns in 
Florida and information on certifying conditions.19 
However, the report does not contain summary 
demographic information on medical marijuana 
patients. 
Use of Marijuana in Modern Medicine 
There is a growing interest in the research and use of 
medical marijuana and marijuana-based 
pharmaceuticals for the treatment and management of 
a variety of conditions. After a thorough review of all 
medical marijuana clinical studies by the National 
Academy of Sciences, Engineering, and Medicine, the 
panel concluded there was conclusive evidence that 
cannabis-based medicines are effective for the 
treatment of chronic pain, chemotherapy-induced 
nausea and vomiting, and symptoms of spasticity 
symptoms in MS patients.17 In a study by Crowell20 the 
most common reasons for indicating the use of 
medical marijuana among a group of patients in New 
Jersey were intractable skeletal spasticity, chronic 
pain, MS, and inflammatory bowel disease. Medical 
marijuana is generally indicated to be beneficial for 
the treatment of several conditions such as chronic 
non-malignant pain, poor appetite, nausea, depression, 
anxiety, arthritis, bruxism, chemotherapy-induced 
nausea and vomiting, chronic fatigue, depression, 
diabetes symptoms, spasticity from MS, epileptic 
seizures, and intestinal disorders.21  
While medical marijuana has many potential uses, the 
primary therapeutic use is to treat chronic pain in 
adults. Chronic non-cancer pain is the most commonly 
cited use of medical marijuana in the U.S., Canada, 
and the Netherlands.22 While there is the general 
public perception that marijuana may be used to treat 
pain, to date, few large randomized controlled trials 
have been conducted to test this assumption. A 
systematic review of 15 trials on the effect of medical 
marijuana on non-cancer pain reported significant 
improvements in patients with neuropathic pain, and 
moderate improvement in fibromyalgia and 
rheumatoid arthritis.23 Another systematic review of 
24 randomized controlled trials provided some 
evidence for the effectiveness of medical marijuana in 
the treatment of chronic pain conditions such as 
arthritic pain, headache, neuropathic pain, and visceral 
pain, especially by inhalation.24 However, more 
research is needed to establish the efficacy of different 
formulations of medical marijuana for pain treatment. 
Chronic pain is a persistent and widespread public 
health problem, and opioids are commonly prescribed 
to treat pain. An Institute of Medicine report listed 
several causes of chronic pain prevalence which 
included: 1) rising obesity; 2) increase in number of 
cancer survivors; 3) complications from surgical 
procedures; and 4) musculoskeletal disorders in older 
adults.25 Medical marijuana is considered a safer 
alternative than opioids for patients who may be at risk 
for addiction and overdose. One national study 
identified that in states with medical marijuana laws 
and prescription drug monitoring programs, opioid-
related deaths substantially decreased.26 Another 
national study reported that in states with medical 
marijuana laws, the opioid overdose rate decreased 
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over time, from 20% in the first year to 33% by the 
sixth year since enactment of the laws.27 Population-
wide opioid overdose deaths have decreased in states 
that have not stringently regulated the operation of 
medical marijuana dispensaries and are permitted 
more latitude in dispensing practices.28-32 For many 
pain patients, medical marijuana may be a safer 
alternative than prescription opioids. 
Methods of Consuming Medical Marijuana 
There are different ways for patients to use medical 
marijuana effectively. Marijuana is primarily inhaled, 
but other modes of use include ingestion of food 
prepared with marijuana oils (i.e., edibles), and topical 
applications. In Florida, products available for 
purchase include vape pens, vaporizers, capsules, oral 
syringes, drops, oils, topical creams, and smokable 
marijuana.33 There is also distinction between low-
THC cannabis, defined as products with less than 
0.8% of THC and more than 10% of CBD, compared 
with medical marijuana, which encompasses all forms 
of the plant – including low-THC marijuana – 
dispensed by a MMTC to qualified patients. 
Qualifying Conditions for Medical Marijuana in 
Florida 
In July 2014, the Florida Legislature passed the 
Compassionate Medical Use Act. In January 2015 
qualified physicians were permitted to issue patient 
orders for low-THC cannabis under limited 
conditions, and in August 2016 the first low-THC 
cannabis and medical marijuana were made available. 
In February 2017, Medical Marijuana Use Registry 
identification cards were issued to patients, and 
qualified physicians could issue these cards to 
patients. In March 2019, smokable marijuana became 
available for qualified patients, which was previously 
not permitted.34 Once a patient’s identification card 
application is approved, the patient can fill an order at 
one of the licensed MMTCs following the physician’s 
recommendation.  
The following medical conditions qualify a patient to 
receive medical marijuana: cancer, epilepsy, 
glaucoma, HIV-positive status and AIDS, post-
traumatic stress disorder (PTSD), amyotrophic lateral 
sclerosis (ALS), Crohn’s Disease, Parkinson’s 
Disease, MS, terminal conditions, and chronic non-
malignant pain.19 As of February 15, 2019, 2,082 
physicians had completed the required training course 
on medical marijuana, which needs to be renewed 
every two years.35 As of April 2019, there were 114 
licensed MMTCs. In 2018 (January through 
September), 1,070 physicians issued 174,254 
certifications to 136,274 patients for low-THC 
cannabis and medical marijuana.19  
Medical marijuana is currently being used primarily 
for pain management both in Florida and nationwide. 
Out of all the certifications in Florida, the top five 
conditions included: chronic non-malignant pain 
(27.7%), qualifying medical conditions other than 
chronic non-malignant pain or terminal conditions 
(27.3%), PTSD (23.6%), cancer (9.8%), and epilepsy 
(2.5%). There have been some advances to understand 
dispensing practices based on nationwide patient 
registry information. Analysis of state registry data 
nationwide for medical marijuana use (1999-2017) 
reported that chronic pain was the most common 
condition indicated (62%), followed by spasticity from 
MS, chemotherapy-induced nausea and vomiting, 
PTSD, and cancer.3 To bolster the case for responsible 
recommendations, over 85% of qualifying conditions 
(chromic pain, chemotherapy-induced nausea and 
vomiting, and spasticity from MS) were identified by 
the 2017 National Academies report as conditions with 
either conclusive or substantial evidence of 
therapeutic effectiveness.17 
Florida Policy for Physicians 
The Florida Department of Health Office of Medical 
Marijuana Use maintains a list of physicians who are 
permitted to order low-THC cannabis, medical 
marijuana, and drug delivery devices. Under current 
law, physicians certified to work in Florida are 
protected against criminal penalties for recommending 
medical marijuana to patients with qualifying 
conditions within specified guidelines. According to 
the law, a physician is authorized to order medical 
marijuana to treat patients suffering from a qualifying 
condition if the physician holds an active, unrestricted 
license as a physician (f.s. 458) or osteopathic 
physician (f.s. 459) and has successfully completed 
training.34 Training includes a two-hour course, per 
qualifying condition, and passing of an exam issued by 
their respective certifying Boards (Florida Board of 
Osteopathic Medicine or Florida Board of Medicine) 
each year. The $250 course covers information on 
rules and regulations, allowable conditions and 
delivery mechanisms, legal restrictions, and decision 
making for physicians on patient eligibility.36  
Certifying Boards maintain documentation on how 
many patients are certified, the type of delivery 
mechanism used by patients, and the quantity of 
medical marijuana recommended. For certifying 
patients, physicians may only issue a certification with 
an in-person patient visit, and certifications cannot be 
issued through a telemedicine consultation. Qualified 
physicians are only able to issue three 70-day supplies 
in each consultation. Physicians are required to 
maintain a treatment plan that includes the dosage, 
route of administration (oral, skin, etc.), planned 
duration, monitoring of symptoms or other indicators 
of toleration. A recommending physician who violates 
these guidelines commits a first-degree misdemeanor 
punishable by fines up to $1,000 (f.s. 775.083(1)(d)) 
or imprisonment not exceeding one year (f.s. 
775.082(4)).34  
Clinical Challenges 
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A commentary by a physician group on their clinical 
experience in certifying patients for medical marijuana 
illustrates the difficulties physicians may face to meet 
the needs of their patients.37 They conducted a chart 
review of 166 patients in their practice in Chicago, 
Illinois and identified five factors which especially 
posed challenges for their practice. These included the 
following: 
1. Suboptimal knowledge of effectiveness, 
dosage, delivery mechanism, indications, and 
drug interactions; 
2. No educational standards for dispensary and 
medical staff training; 
3. Poor communication and coordination of 
patient care; 
4. Challenges with supply of dosing options; 
and 
5. Access barriers for those wanting medical 
marijuana treatment. 
Areas for improvement were identified in the 
commentary. For example, in terms of dispensary 
staff, there was a shortage of pharmacists and other 
trained staff, so if more pharmacists were available, 
they would be able to help with issues regarding 
potential drug interactions and dosing. Another issue 
involves the number of medical marijuana choices 
available for dosing (e.g., edibles, patches, oils, 
creams, inhalation). This menu of options can create 
confusion for physicians and patients in terms of 
dosing formulas to best address patient’s symptoms 
while minimizing side effects. In the commentary, the 
authors recommended better data-driven guidelines on 
these issues and potential drug interactions with other 
medications (e.g., opioids, benzodiazepines, and 
antidepressants).37 There is also the important role for 
medical marijuana cultivators and dispensaries to only 
supply the most effective medical marijuana 
preparations to solve issues of quality control, supply 
and product demand.  
Barriers for Access to Medical Marijuana 
Because of the current regulatory environment, there 
are barriers to medical marijuana access for patients. 
These include patient hesitancy to discuss medical 
marijuana options with physicians as well as 
paperwork burden and regulatory hurdles to become a 
qualified physician in order to start issuing 
certifications.38 Studies have reported that medical 
marijuana use is more predominant among European 
Americans and less likely among Black, Latino, Asian 
and foreign-born individuals.6,39 There are various 
reasons for the discrepancies in access such as 
disposable income, stigma, and physician 
preferences.39,40 Patients might feel stigma in asking 
their personal physician to issue a certification for 
medical marijuana use, or their personal physician 
might not be certified to recommend medical 
marijuana.38 A review article focused on barriers to 
medical marijuana access reported that medical 
marijuana use is more common among individuals 
who are employed, earn high incomes, and have health 
insurance.39  
In addition to costs such as co-payments for the 
doctor’s visit, there are fees associated with obtaining 
a medical marijuana card. In Arizona, there is a $150 
initial and renewal registration fee for the state’s 
program.39 In Florida, there is no insurance coverage 
for medical marijuana, and private insurers cite 
reasons for non-coverage including lack of FDA 
approval and the federal classification of marijuana as 
a Schedule 1 drug. For Florida residents, patients first 
need a medical consultation which costs $250 or more 
to be certified as a medical marijuana patient; 
however, the medical consultation cost may vary.41 
Next, there is an initial $75 application fee for the 
identification card, which is valid for one year. Costs 
for the product which is obtained at the dispensary 
vary depending on the medical marijuana delivery 
option. If the patient purchases their own vaporizer to 
use with pre-filled cartridges, the unit costs between 
$100-$300 and cartridges cost between $35 and $60 
depending on the amount and type or strain. Patients 
must be recertified every seven months which incurs 
another physician visit. Therefore, total costs for the 
first year of use can easily exceed $600, which could 
be a burden for low-income patients. 
Physicians certified to recommend medical marijuana 
can charge what they deem as reasonable for a 
consultation. Furthermore, the cost of medical 
marijuana can range from $50 to $150 for certain 
amounts at dispensaries. Currently, dispensaries in 
Florida are not equally distributed throughout the 
state, thus reducing access to some populations, 
especially in rural areas. This may exacerbate 
equitable access and contribute to missed economic 
activity for Florida. In addition to the direct economic 
benefits for Florida from increased tax revenues which 
are redistributed to healthcare, there are other benefits 
of medical marijuana. These include reducing arrests 
for marijuana possession, which disproportionately 
affect minority communities, and sanctioning the 
medical and compassionate use of medical marijuana.4 
 
DISCUSSION 
This review summarized numerous recent clinical 
studies and concludes that there is evidence that 
medical marijuana provides therapeutic benefits to 
patients for a variety of health conditions, but 
particularly for chronic pain patients, cancer patients 
with chemotherapy-induced nausea and vomiting, and 
MS patients with spasticity symptoms. However, there 
is a need for more controlled studies, especially in the 
areas of cancer pain, intestinal disorders, and mental 
health. Since medical marijuana is being 
recommended for patients suffering from PTSD and 
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generalized anxiety disorder, more research is needed 
to demonstrate improvement in mental health 
outcomes for these debilitating conditions. Since this 
is a scoping review, there was no attempt to assess the 
quality of the controlled studies identified and 
included, therefore there are limitations in terms of 
recommendations for policy or practice since the rigor 
of the clinical studies was not assessed.42  
In terms of the Florida regulatory environment, some 
of the laws governing dispensaries and MMTCs are 
currently experiencing legal challenges, so there could 
be future changes in the number of MMTCs allowed 
to operate in Florida for example, which is currently 
capped. Increasing the number of dispensaries that 
could reach into rural areas of the state would increase 
access. In the current policy environment, challenges 
also remain in terms of physician education and 
reducing stigma among healthcare providers to 
become a certifying physician. From the physician 
perspective, there is stigma from becoming qualified 
to provide patients with medical marijuana 
certifications. Since prescribing medical marijuana is 
illegal under federal law, according to an investigative 
report, physicians fear they might be at risk of being 
blacklisted by hospital systems, nursing homes, or 
hospices, which rely on Medicaid and Medicare 
reimbursement funds; moreover, another issue which 
might contribute to stigma occurs when physicians 
with poor reputations are filling the void to work in 
MMTCs.43 
In the research arena, challenges remain to provide the 
funding necessary to establish the research 
infrastructure at Florida’s public universities and 
research institutes given the existing federal policies 
and shifting priorities for state research dollars. 
Currently, there is limited research on medical 
marijuana being conducted in Florida. One recent 
study funded by the Florida legislature with glioma 
patients at Moffitt Cancer Center in Tampa, Florida 
reported that only a third of patients were using 
medical marijuana and received benefits from its use 
for symptoms including pain, nausea, poor appetite, 
and anxiety, but they had received the 
recommendation from friends or family rather than a 
medical provider.44 The study highlighted the need for 
more patient and physician communication on the 
potential benefits of medical marijuana for some 
cancer patients. Future research in medical marijuana 
will hopefully lead to improved therapeutic benefits 
for patients and greater understanding of the effects of 
cannabinoids on human health. 
Conclusions 
This scoping review has identified ongoing and past 
research efforts to demonstrate the therapeutic benefits 
of medical marijuana and points to some possible 
areas of investigation for health policy research. 
Because Florida law keeps medical marijuana in the 
health domain and the drug has not been 
decriminalized, regulatory activities remain in the 
Florida Department of Health instead of other agencies 
which regulate alcohol and tobacco, as was done in 
Colorado for example.45 One of the greatest challenges 
in Florida is the need for quality physician training and 
for more physicians to receive certification to improve 
physician/patient communication and patient 
education on this emerging therapy option. Moreover, 
there is an important role for public health in policy 
development around excise and sales taxes and 
collecting population-wide state data on marijuana use 
ahead of the possibility of expanded decriminalization 
policies. 
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